Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Imclone systems (IMCL) -- Ignore unavailable to you. Want to Upgrade?

To: caly who wrote (958)	9/3/1999 5:49:00 PM
From: Gordon James	Read Replies (1) \| Respond to of 2515

calypso, You're probably right that this trial is officially still in progress - I just wanted to point out that it appears to be something along the lines of "dead, just not buried yet", and so nothing to get excited about for people who may have just ran across it. Reason I say this is that the trial was initiated way back in March of 1996, and the "health professional abstract" for the trial on NCI Cancernet indicates that "up to 12 evaluable patients will be studied", but both NCI and ImClone web page show the trial as still open for enrollment. If they haven't gotten 12 patients enrolled in 3.5 years, doesn't look like a trial that's going anywhere. Still possible that they'll complete this trial at some point and announce some results, but I'm not too excited about it given the current status... Cheers, Gordon P.S. Search Recombinant Capital for more info on this trial including press release: recap.com See the "health professional abstract" via a link on the NCI page for this trial that calypso provided.